Shomron Ben-Horin
Sheba Medical Center
Internal medicineRadiologySurgeryOdds ratioAntibodyRetrospective cohort studyTumor necrosis factor alphaImmunologyColitisVedolizumabInfliximabCapsule endoscopyInflammatory bowel diseaseDiseaseCrohn's diseaseAdalimumabUlcerative colitisIn patientMedicineGastroenterology
302Publications
58H-index
7,988Citations
Publications 331
Newest
#1Shomron Ben-Horin (Sheba Medical Center)H-Index: 58
#2Lena Novack (BGU: Ben-Gurion University of the Negev)H-Index: 25
Last. Minhu ChenH-Index: 56
view all 14 authors...
Background and Aims null Starting biologic treatment early in the course of inflammatory bowel disease (IBD) may be associated with higher efficacy, especially in Crohn's disease (CD). null Methods null This was a systematic review and individual-patient data meta-analysis of all placebo-controlled trials of biologics approved for IBD at study inception (October 2015), using Vivli data-sharing platform. The primary outcome was the proportional biologic/placebo treatment effect on induction of re...
Source
#1Hadar Edelman-Klapper (TAU: Tel Aviv University)H-Index: 1
#2Eran Zittan (Emek Medical Center)H-Index: 11
Last. Iris Dotan (TAU: Tel Aviv University)H-Index: 51
view all 35 authors...
Background null Patients with inflammatory bowel diseases (IBD), specifically those treated with anti-tumor-necrosis-factor (TNF)α biologics are at high risk for vaccine preventable infections. Their ability to mount adequate vaccine responses is unclear. null Aim null To assess serologic responses to mRNA-COVID-19 vaccine, and safety profile, in patients with IBD stratified according to therapy, compared to healthy controls (HC). null Methods null Prospective, controlled, multi-center Israeli s...
Source
BACKGROUND There are currently no nationwide data on the epidemiology of inflammatory bowel diseases (IBD) in Israel. We aimed to determine the population-based epidemiological trends of IBD in the diverse Israeli population. METHODS Health-administrative data were retrieved from all 4 Israeli health maintenance organizations, insuring 98% of the population, using validated identification algorithms. National trends were determined using Joinpoint regression analysis calculating annual percent c...
Source
#1A Levartovsky (Sheba Medical Center)H-Index: 2
#2Shomron Ben-Horin (Sheba Medical Center)H-Index: 58
Source
#1Ehud Mekori-Domachevsky (TAU: Tel Aviv University)H-Index: 4
#2Shomron Ben-Horin (TAU: Tel Aviv University)H-Index: 58
Source
Infliximab and vedolizumab are effective treatments for inflammatory bowel disease (IBD), although associated with adverse events (AE). While low or non-existent drug levels and positive antidrug antibodies have been associated with therapeutic failure, there is no clear association between higher drug levels and AE. A cross-sectional study consisting of Crohn’s disease (CD) and ulcerative colitis (UC) patients receiving infliximab or vedolizumab at the Sheba Medical Center was performed. Patien...
Source
#1Hadar Edelman-Klapper (TAU: Tel Aviv University)H-Index: 1
#2Eran Zittan (Emek Medical Center)H-Index: 11
Last. Henit Yanai (TAU: Tel Aviv University)H-Index: 20
view all 33 authors...
BackgroundPatients with inflammatory bowel diseases (IBD), specifically those treated with anti-tumor necrosis factor (TNF) biologics are at high risk for vaccine preventable infections. Their ability to mount adequate vaccine responses is unclear. null Aimto assess immune responses to mRNA-COVID-19 vaccine, and safety profile, in patients with IBD stratified according to therapy, compared to healthy controls (HC). null MethodsProspective, controlled, multi-center Israeli study. Subjects enrolle...
Source
#1Eyal Klang (Sheba Medical Center)H-Index: 18
#2Uri Kopylov (Sheba Medical Center)H-Index: 50
Last. Martin BuckleyH-Index: 24
view all 13 authors...
Background and study aims: Deep learning (DL) for video capsule endoscopy (VCE) is an emerging research field. It has shown high accuracy for the detection of Crohn’s disease (CD) ulcers. Non-steroidal anti-inflammatory drugs (NSAIDS) are commonly used medications. In the small bowel, NSAIDs may cause a variety of gastrointestinal adverse events including NSAID-induced ulcers. These ulcers are the most important differential diagnosis for small bowel ulcers in patients evaluated for suspected CD...
Source
#1Lior Dar Antaki (Sheba Medical Center)
#2Alexander Volkov (Sheba Medical Center)H-Index: 9
Last. Shomron Ben-Horin (Sheba Medical Center)H-Index: 58
view all 3 authors...
Source
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.